Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | CHIEF FINANCIAL OFFICER | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common sharesSEC Table I · non-derivative | Direct | 246,855 |
Reported balance
After 2026-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 3,846 · Balance 246,855 F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2024 Filed Sep 4, 2024 22:33 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022812 · form4-09042024_050901.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,481 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 20:30 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020516 · form4-08012024_040803.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,439 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018984 · form4-07022024_090731.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,397 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 22:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015201 · form4-06032024_100602.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,355 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| May 16, 2024 Filed May 21, 2024 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit (right to receive value of a share) · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013981 · form4-05212024_050503.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778,958 Underlying: Common Shares · 50,000 shares Expires 2034-05-16 F3 · security: On May 16, 2024, Robert Andrade was awarded restricted share units to acquire 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this award may be released from restriction as of May 16, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027, 100% of the total number of shares subject to this award shall be releaseed. Read SEC document |
| May 16, 2024 Filed May 21, 2024 21:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001415889-24-013981 · form4-05212024_050503.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,958 Underlying: Common Shares · 100,000 shares Expires 2034-05-16 F1 · security: On May 16, 2024, Robert Andrade was granted incentive stock options to purchase 100,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of May 16, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| April 30, 2024 Filed May 2, 2024 21:03 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012018 · form4-05022024_090505.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,313 F1 · security: Represents shares released from restriction from shares awarded 3-31-2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | PurchaseCommon shares | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010059 · form4-04032024_050402.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,271 F1 · security: Represents release of restriction from shares awarded 3-31-2023. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 20:22 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 13,975 | $10.90 | $152,345.67 |
DisclosureSEC source: 0001415889-24-009204 · form4-03272024_080308.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,771 F1 · security: Represents shares sold pursuant to a 10b5-1 plan adopted August 16, 2023. Read SEC document |
| March 25, 2024 Filed Mar 25, 2024 23:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 13,975 | $11.00 | $153,690.06 |
DisclosureSEC source: 0001415889-24-009068 · form4-03252024_110359.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,746 F1 · shares: Represents shares sold pursuant to a 10b5-1 plan adopted on August 16, 2023. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 15,000 | $10.41 | $156,150.00 |
DisclosureSEC source: 0001415889-24-000781 · form4-01052024_100121.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,721 F2 · security: Represents shares sold pursuant to a 10b5-1 plan adopted on June 14, 2023. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 15,000 | $10.64 | $159,600.00 |
DisclosureSEC source: 0001415889-24-000781 · form4-01052024_100121.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,721 F1 · security: Represents shares sold pursuant to a 10b5-1 plan adopted on June 14, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 25,000 | $2.45 Strike: $2.45 | $61,250.00 |
DisclosureSEC source: 0001415889-23-010459 · form4-06302023_080609.xml · derivative · entry 5 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,000 Underlying: Options · 25,000 shares Expires 2026-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Represents options granted on July 5, 2016, with a strike price of $2.45 and expiration date of July 5, 2026. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 25,000 | $2.45 | $61,250.00 |
DisclosureSEC source: 0001415889-23-010459 · form4-06302023_080609.xml · nonDerivative · entry 4 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Shares aquired through the exercise of option contract with a strike price of $2.45 and an expiration date of July 5, 2026. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 7,500 | $8.82 | $66,150.00 |
DisclosureSEC source: 0001415889-23-010459 · form4-06302023_080609.xml · nonDerivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,721 F3 · security: Represents shares sold pursuant to a 10b5-1 plan on June 30, 2023. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 7,500 | $8.97 | $67,275.00 |
DisclosureSEC source: 0001415889-23-010459 · form4-06302023_080609.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,221 F2 · security: Represents shares sold pursuant to a 10b5-1 plan on June 29, 2023. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 10,000 | $8.99 | $89,900.00 |
DisclosureSEC source: 0001415889-23-010459 · form4-06302023_080609.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,721 F1 · security: Represents shares sold pursuant to a 10b5-1 plan on June 28, 2023. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:25 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit (right to receive value of a share) · Derivative | 37,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005781 · form4-04032023_080421.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,500 Underlying: Common Shares · 37,500 shares Expires 2031-12-21 F3 · date: 1. On March 31, 2023, Robert Andrade was awarded restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: 1/3 of the shares subject to this award shall be released from restriction as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this award shall be released. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:25 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001415889-23-005781 · form4-04032023_080421.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,000 Underlying: Common Shares · 75,000 shares Expires 2033-03-31 F1 · security: On March 31, 2023, Robert Andrade was granted incentive stock options to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 2. 1/3 of the shares subject to this option shall vest immediately and may be exercised as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 5,500 | $9.61 | $52,867.10 |
DisclosureSEC source: 0001415889-22-013102 · form4-12302022_091249.xml · nonDerivative · entry 3 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,721 F3 · security: Represents shares sold pursuant to a 10b5-1 plan on December 30, 2022. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 5,500 | $9.57 | $52,661.40 |
DisclosureSEC source: 0001415889-22-013102 · form4-12302022_091249.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,221 F2 · security: Represents shares sold pursuant to a 10b5-1 plan on December 29, 2022. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon shares | 11,000 | $9.61 | $105,759.50 |
DisclosureSEC source: 0001415889-22-013102 · form4-12302022_091249.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,721 F1 · security: Represents shares sold pursuant to a 10b5-1 plan on December 28, 2022. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 15:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Disposition to issuerCommon shares | 19,052 | $8.54 | $162,704.08 |
DisclosureSEC source: 0001415889-22-009828 · form4-09222022_080943.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,721 F2 · security: On September 21, 2022, 19,052 shares were netted back to the company to pay the taxes on the common shares released from restriction. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 15:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon shares | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009828 · form4-09222022_080943.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,773 F1 · security: On September 21, 2022, 37,500 restricted share units were released from their restriction. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 22:48 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit (right to receive value of a share) · Derivative | 37,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151822 · tm2135965-2_4seq1.xml · derivative · entry 2 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 37,500 shares Expires 2031-12-20 F2 · security: On December 20, 2021, Robert Andrade was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3 · derivative.exercise_date: Item vests 100% upon FDA approval of PEDMARKTM. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 22:48 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001104659-21-151822 · tm2135965-2_4seq1.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2031-12-20 F1 · security: On December 20, 2021, Robert Andrade was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F3 · derivative.exercise_date: Item vests 100% upon FDA approval of PEDMARKTM. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 15:58 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-21-076222 · tm2118436-2_4seq1.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2031-06-02 F1 · security: On June 2, 2021, Robert Andrade was granted an incentive stock option to purchase 100,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of June 2, 2022 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 31, 2024 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 12,874 | $5.71 | $73,510.54 |
DisclosureSEC source: 0001104659-20-096098 · tm2028839d2_4.xml · nonDerivative · entry 5 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,273 F5 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.63 to $5.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 38,900 | $5.68 | $220,952.00 |
DisclosureSEC source: 0001104659-20-096098 · tm2028839d2_4.xml · nonDerivative · entry 4 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,147 F4 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.39 to $5.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 38,828 | $5.77 | $224,037.56 |
DisclosureSEC source: 0001104659-20-096098 · tm2028839d2_4.xml · nonDerivative · entry 3 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,047 F3 · price: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 323,861 shares from an August 18, 2010 grant of 323,961 shares. The price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $5.62 to $5.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon shares | 97,136 | $6.17 | $599,329.12 |
DisclosureSEC source: 0001104659-20-096098 · tm2028839d2_4.xml · nonDerivative · entry 2 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,875 F2 · price: Represents shares sold per a net exercise of shares to cover the proceeds necessary for the exercise of 323,861 shares at a USD$1.85 exercise price from the August 18, 2010 grant of 323,961 shares with expiration of August 18, 2020. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 20:06 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon shares | 323,961 | $1.85 | $599,327.85 |
DisclosureSEC source: 0001104659-20-096098 · tm2028839d2_4.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents options granted on August 18, 2010 with a CAD$ strike price of $2.43 CAD converted at 0.76 CAD/USD exchange ratio with an expiration of August 18, 2020. Read SEC document |
| May 15, 2020 Filed May 15, 2020 17:58 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001104659-20-062414 · tm2019938d3_4.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2030-05-15 F1 · security: On May 15, 2020, Robert Andrade was granted an incentive stock option to purchase 125,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of May 15, 2021 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of May 15, 2023 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 15:28 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001144204-19-018578 · tv518388_4.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2026-04-04 F1 · security: On April 4, 2019, Robert Andrade was granted an incentive stock option to purchase 80,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of April 4, 2020 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 4, 2022 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:33 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Stock | 17,050 | $1.44 | $24,552.00 |
DisclosureSEC source: 0001144204-18-045375 · tv501320_form4.xml · nonDerivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 9, 2018 02:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001144204-18-006729 · tv485382_4.xml · derivative · entry 1 Andrade Robert · CIK 0001468308 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2025-02-06 F1 · security: On February 6,, 2018, Robert Andrade was granted an incentive stock option to purchase 500,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: 1/3 of the shares subject to this option shall vest immediately and may be exercised as of February 6, 2019 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 6, 2021 and thereafter, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.